AP9600900A0 - Quinoline and quinazoline compounds useful in therapy - Google Patents

Quinoline and quinazoline compounds useful in therapy

Info

Publication number
AP9600900A0
AP9600900A0 AP9600900A AP9600900A AP9600900A0 AP 9600900 A0 AP9600900 A0 AP 9600900A0 AP 9600900 A AP9600900 A AP 9600900A AP 9600900 A AP9600900 A AP 9600900A AP 9600900 A0 AP9600900 A0 AP 9600900A0
Authority
AP
ARIPO
Prior art keywords
quinoline
therapy
compounds useful
quinazoline compounds
quinazoline
Prior art date
Application number
AP9600900A
Other versions
AP715A (en
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9526546.8A priority Critical patent/GB9526546D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of AP9600900A0 publication Critical patent/AP9600900A0/en
Application granted granted Critical
Publication of AP715A publication Critical patent/AP715A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04Ortho-condensed systems
AP9600900A 1995-12-23 1996-12-19 Quinoline and quinazoline compounds useful in therapy. AP715A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy

Publications (2)

Publication Number Publication Date
AP9600900A0 true AP9600900A0 (en) 1997-01-31
AP715A AP715A (en) 1998-12-30

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
AP9600900A AP715A (en) 1995-12-23 1996-12-19 Quinoline and quinazoline compounds useful in therapy.

Country Status (34)

Country Link
US (3) US6103738A (en)
EP (1) EP0877734B1 (en)
JP (1) JP3070958B2 (en)
KR (1) KR19990076693A (en)
AP (1) AP715A (en)
AR (1) AR005166A1 (en)
AT (1) AT194598T (en)
AU (1) AU708979B2 (en)
BG (1) BG102559A (en)
BR (1) BR9612263A (en)
CA (1) CA2236814C (en)
CO (1) CO4480106A1 (en)
CZ (1) CZ197698A3 (en)
DE (2) DE69609353D1 (en)
DK (1) DK0877734T3 (en)
ES (1) ES2151192T3 (en)
GB (1) GB9526546D0 (en)
GR (1) GR3034225T3 (en)
HN (1) HN1996000082A (en)
HR (1) HRP960616A2 (en)
HU (1) HU9903560A3 (en)
IS (1) IS4731A (en)
MA (1) MA26414A1 (en)
NO (1) NO982913L (en)
NZ (1) NZ325248A (en)
OA (1) OA10703A (en)
PL (1) PL327610A1 (en)
PT (1) PT877734E (en)
SK (1) SK81698A3 (en)
TN (1) TNSN96161A1 (en)
TR (1) TR199801195T2 (en)
WO (1) WO1997023462A1 (en)
YU (1) YU68896A (en)
ZA (1) ZA9610784B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
WO2002018348A2 (en) 2000-08-31 2002-03-07 F. Hoffman-La Roche Ag Quinazoline derivatives as alpha-1 adrenergic antagonists
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
WO2004029051A1 (en) 2002-09-26 2004-04-08 Pfizer Limited Pyrazole amides for treating hiv infections
DK1615909T3 (en) 2003-04-23 2008-11-17 Glaxo Group Ltd Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
ES2369652T3 (en) 2003-09-26 2011-12-02 Exelixis Inc. C-met modulators and methods of use.
NZ587548A (en) * 2004-06-24 2012-05-25 Vertex Pharma Pharmaceutical uses of N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
EP1993360B1 (en) 2005-12-28 2017-02-08 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
BRPI0808772A2 (en) * 2007-03-14 2014-08-12 Exelixis Inc Hedgehog inhibitors
JP5362839B2 (en) * 2008-11-14 2013-12-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Quinazoline derivatives as NK3 receptor antagonists
EA026425B1 (en) 2009-01-16 2017-04-28 Экселиксис, Инк. Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
KR20110130487A (en) * 2009-03-23 2011-12-05 시플라 리미티드 Process for the preparation of doxazosin and salts thereof
PT2473487T (en) 2009-09-03 2017-01-04 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
CN103596603B (en) 2011-03-11 2016-01-20 W.L.戈尔及同仁股份有限公司 Improved immobilized biological entities
US20140309184A1 (en) * 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
KR101910724B1 (en) * 2014-03-24 2018-10-22 광동 쫑성 파마세티컬 컴패니, 리미티드 Quinoline derivatives as smo inhibitors
JP2017530175A (en) 2014-10-07 2017-10-12 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Cocrystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CA2236814A1 (en) 1997-07-03
US20030220332A1 (en) 2003-11-27
HRP960616A2 (en) 1998-06-30
US6750214B2 (en) 2004-06-15
AU708979B2 (en) 1999-08-19
CO4480106A1 (en) 1997-07-09
SK81698A3 (en) 2000-04-10
EP0877734A1 (en) 1998-11-18
DK0877734T3 (en) 2000-11-20
PL327610A1 (en) 1998-12-21
HU9903560A3 (en) 2000-07-28
JP3070958B2 (en) 2000-07-31
HN1996000082A (en) 1997-06-30
BG102559A (en) 1999-03-31
US20020049322A1 (en) 2002-04-25
US6103738A (en) 2000-08-15
HU9903560A2 (en) 2000-05-28
YU68896A (en) 1999-07-28
PT877734E (en) 2000-12-29
CZ197698A3 (en) 1999-03-17
IS4731A (en) 1998-04-29
NO982913L (en) 1998-07-30
OA10703A (en) 2002-11-28
CA2236814C (en) 2001-09-18
JPH11501668A (en) 1999-02-09
ZA9610784B (en) 1998-06-22
ES2151192T3 (en) 2000-12-16
DK877734T3 (en)
AU1371997A (en) 1997-07-17
AP715A (en) 1998-12-30
KR19990076693A (en) 1999-10-15
GR3034225T3 (en) 2000-12-29
DE69609353D1 (en) 2000-08-17
GB9526546D0 (en) 1996-02-28
WO1997023462A1 (en) 1997-07-03
EP0877734B1 (en) 2000-07-12
AT194598T (en) 2000-07-15
TNSN96161A1 (en) 2005-03-15
NO982913D0 (en) 1998-06-22
DE69609353T2 (en) 2000-12-07
AR005166A1 (en) 1999-04-14
MA26414A1 (en) 2004-12-20
NZ325248A (en) 1999-09-29
TR199801195T2 (en) 1998-10-21
BR9612263A (en) 1999-07-13
US6642242B2 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
US5584086B1 (en) Therapeutic pillow and method
AU690735B2 (en) Spiro-azabicyclic compounds useful in therapy
EG24134A (en) Quinazoline derivatives
AU692104B2 (en) Xanthines and their therapeutic use
GB2298422B (en) Compounds and their use
GB2311403B (en) LCD device and method of forming the same
PL328310A1 (en) Derivatives of quinazoline
IL130181D0 (en) Substituted pyrimidone and pyridone compounds and methods of use
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
ZA9504392B (en) Electroheating apparatus and methods
GB9603095D0 (en) Quinazoline derivatives
GB9607729D0 (en) Quinazoline derivatives
IL136476D0 (en) Security device having multiple security features and method of making same
IL116851D0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
IL117859A (en) Isothiazolones and their uses
GB2310670B (en) Firelogs and firelighters
EP0708482A3 (en) BiCDMOS process technology and structures
IL113343D0 (en) CTLA4 molecules and their uses
ZA9508642B (en) Novel carboxylicatives their preparation and use
GB9606677D0 (en) Process and device
GB9414341D0 (en) Quinazoline derivatives
EP0938505A4 (en) Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
IL113901D0 (en) 1-phenyl-3-dimethylaminopropane compounds their preparation and use
EP1026999A4 (en) Phototherapy methods and systems
EP0782321A3 (en) Combination mouse and area imager